How clinical trials are designed, regulated, and conducted can differ between Europe and the US. From data protection to study procedures and accessibility, understanding these key differences offers valuable insights into what volunteering for a trial looks like — and how your experience may vary depending on where in the world you take part.
Understanding Clinical Trials in Europe and the US
In both Europe and the United States, clinical trials are essential for bringing new treatments from the laboratory to the public. Each region follows strict scientific and ethical standards to ensure the safety and effectiveness of new medicines.
For participants, that means protection and close monitoring at every phase — from early testing to post-approval follow-up. While both systems share the same goal of advancing health, Europe and the US differ in how trials are approved, regulated, and communicated. This can influence aspects from how easily you find a study to how your data is handled.In short: both regions are committed to making safer, more effective medicines available. They simply take different regulatory routes to get there.
&
Regulatory Frameworks
Europe
In Europe, clinical trials are governed by the European Medicines Agency (EMA) and national authorities within each EU member state. Since the EU Clinical Trials Regulation (CTR 536/2014) came into effect, approvals have become more streamlined through the Clinical Trials Information System (CTIS).
For volunteers, this centralised system makes participation easier to track and understand. The CTIS increases transparency, giving the public access to information on all authorised studies, including results once the trial is complete. It also ensures that informed consent, data protection, and ethical oversight are at the heart of every study, strengthening participant trust and safety.
United States
In the US, clinical research is regulated by the Food and Drug Administration (FDA) and monitored by Institutional Review Boards (IRBs), which safeguard participant rights and welfare. Before a study begins, sponsors must submit an Investigational New Drug (IND) application to the FDA, demonstrating that the trial is scientifically sound and ethically designed.For participants, the US framework often allows for faster study initiation and a wide range of early-phase, innovative research opportunities. Local IRBs also ensure that studies reflect the needs of their specific patient communities, helping volunteers feel more supported and heard.
Clinical Trial Process Comparison
When comparing Europe vs. US clinical trials, several key differences affect how participants join and experience a study:
- Application pathway: Europe’s CTIS enables one submission for multi-country trials, giving participants access to studies across several nations. In the US, submissions go to the FDA and local IRBs, resulting in a more localised process.
- Ethics approval: In Europe, ethics committees review studies nationally or regionally; in the US, independent IRBs oversee trials closer to where participants live.
- Transparency: The EU publishes full trial results in the CTIS database; the US uses ClinicalTrials.gov, a widely accessible portal for patients to search for studies.
- Timelines: The US process can be faster for smaller, early-stage trials, while Europe’s approach supports large, multinational research.
Both systems ultimately prioritise participant safety, data integrity, and informed consent, ensuring volunteers are protected and respected wherever they take part.
Impact on Researchers and Sponsors
For sponsors, navigating clinical trial regulations in Europe can be complex due to varying national interpretations, but the new regulation has simplified collaboration. In the US, researchers benefit from a more centralized regulatory dialogue with the FDA.
European sponsors often value the multi-country access to diverse patient populations, while US sponsors appreciate the speed and flexibility of FDA-led studies.
Impact on Volunteers and Patients
For most participants, the clinical trial journey in Europe and the US feels more similar than different. Both regions require informed consent, ensure constant safety monitoring, and prioritise the well-being of every volunteer.
Where the experience may differ is in accessibility and communication. In Europe, the CTIS platform makes it easier for the public to find information about recruiting trials, results, and sponsors. In the US, ClinicalTrials.gov plays a similar role — with thousands of ongoing studies across medical fields.
In both regions, there’s growing recognition that volunteers are partners in research, not just participants. This has led to more patient-centric study designs, simplified language in trial materials, and improved feedback loops, helping patients feel more informed, valued, and connected to the purpose of their participation.
Advances in the European Clinical Trials Landscape
Europe has made major progress in making research more participant-friendly. The EU Clinical Trials Regulation and the EMA’s digital platforms simplify participation, reduce delays, and make results easier for the public to access.
Recent advances that benefit volunteers include:
- Digital and decentralised trials that allow participants to contribute from home or local clinics.
- Improved collaboration between research institutions and healthcare providers for smoother patient referral.
- A stronger focus on trust and transparency, helping participants understand the value of their contribution.
These improvements make clinical trials in Europe more accessible, inclusive, and transparent — opening the door for more people to take part safely and confidently.
Future Outlook: Europe and the US in Global Research
While the US has long led in the number of clinical studies, Europe is closing the gap and adopting more efficient, patient-centred practices. As both regions continue to align through shared values of innovation, safety, and transparency, the global research landscape becomes stronger and more connected.
For volunteers, this means more opportunities to join meaningful studies, better information access, and a growing voice in how research is shaped. Whether in Europe or the US, clinical trial participants are helping to drive progress in medicine — improving health today and for generations to come.
Read also
How and why is a clinical trial started
Clinical trials are defined by the World Health Organization (WHO) as “a type of research that studies new test and treatments and evaluates their effects on human health outcomes”. When we talk about clinical trials, we are talking about research being carried out in human subjects. Developing a clinical trial involves a lot of time […]
Diversity in clinical trials: Minorities and vulnerable groups. Why is it important to include them?
In the broadest sense of the word, we understand ‘vulnerability’ as the susceptibility of an individual to physical or mental harm